DDInter856 DDInter1059
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults. While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.
Levomilnacipran {u} (Compound) resembles {v} (Compound) Milnacipran
Levomilnacipran {u} (Compound) binds {v} (Gene) CYP2C19
Levomilnacipran {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin Uptake Inhibitors
Levomilnacipran {u} (Compound) downregulates {v} (Gene) GJA1
Levomilnacipran {u} (Compound) causes {v} (Side Effect) Infection
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramucirumab
Levomilnacipran {u} may lead to a major life threatening interaction when taken with {v} Doxepin
Levomilnacipran {u} may lead to a major life threatening interaction when taken with {v} Methylene blue
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Iobenguane
Levomilnacipran (Compound) resembles Milnacipran (Compound)
Levomilnacipran (Compound) binds CYP2C19 (Gene)
Levomilnacipran (Compound) is included by Serotonin Uptake Inhibitors (Pharmacologic Class)
Levomilnacipran (Compound) downregulates GJA1 (Gene)
Levomilnacipran (Compound) causes Infection (Side Effect)
Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Levomilnacipran may lead to a major life threatening interaction when taken with Doxepin
Levomilnacipran may lead to a major life threatening interaction when taken with Methylene blue
Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Levomilnacipran may lead to a major life threatening interaction when taken with Iobenguane